Cargando…

Recurrent Endometrial Stromal Sarcoma: Treatment with a Progestin and Gonadotropin Releasing Hormone Agonist

Endometrial stromal sarcoma (ESS) formerly classified as low-grade endometrial stromal sarcoma is a rare uterine malignancy with a good prognosis despite a tendency to recur. Primary surgical management for ESS includes total abdominal hysterectomy and bilateral salpingo-oophorectomy. Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	duPont, Nefertiti Chianti, DiSaia, Philip John
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896615/ https://www.ncbi.nlm.nih.gov/pubmed/20613993 http://dx.doi.org/10.1155/2010/353679

Ejemplares similares

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Potential alternative progestin therapy for low-grade endometrial stromal sarcoma: A case report
por: Maenohara, Shoji, et al.
Publicado: (2020)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Endometrial Stromal Sarcoma Recurrence in the Caecum
por: Chowdri, Nisar A., et al.
Publicado: (2018)

The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer
por: Emons, Günter, et al.
Publicado: (2021)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins
por: Kulkarni, A., et al.
Publicado: (2023)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells
por: Luo, Xiaoping, et al.
Publicado: (2003)

Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia
por: Chen, Junyu, et al.
Publicado: (2022)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Endometrial Preparation for Women Undergoing Embryo Transfer Frozen-Thawed Embryo Transfer With and Without Pretreatment With Gonadotropin Releasing Hormone Agonists
por: Movahedi, Shohreh, et al.
Publicado: (2018)

Comparison of letrozole with gonadotropin-releasing hormone agonist in frozen embryo transfer after recurrent implantation failure: An RCT
por: Khadem Ghaebi, Nayere, et al.
Publicado: (2020)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats
por: TUNGMAHASUK, Doungrut, et al.
Publicado: (2017)

Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
por: Halim, Binarwan, et al.
Publicado: (2022)

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
por: Choi, Seungtaek, et al.
Publicado: (2011)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
por: Han, Eun Jin, et al.
Publicado: (2013)

Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells
por: Scaruffi, Paola, et al.
Publicado: (2019)

Artificial Endometrial Preparation for Frozen-Thawed Embryo Transfer with or without Pretreatment with Depot Gonadotropin Releasing Hormone Agonist in Women with Regular Menses
por: Azimi Nekoo, Elham, et al.
Publicado: (2015)

A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer
por: Zhang, Zhibo, et al.
Publicado: (2019)

Endometrial preparation using gonadotropin-releasing hormone agonist prior to frozen-thawed embryo transfer in women with repeated implantation failure: An RCT
por: Davar, Robab, et al.
Publicado: (2020)

Primary extrauterine endometrial stromal sarcoma: response to hormone therapy
por: Garg, Gunjal, et al.
Publicado: (2009)

Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations
por: Zhou, Ruiqiong, et al.
Publicado: (2023)

Endometrial stromal sarcoma
por: Puliyath, Geetha, et al.
Publicado: (2010)

Retraction Note to: Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells
por: Luo, Xiaoping, et al.
Publicado: (2015)

Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing in vitro Fertilization Treatment: A Randomized Controlled Trial
por: Chen, Qiuju, et al.
Publicado: (2019)

Increased Risk of Pneumonia in Patients Receiving Gonadotropin-Releasing Hormone Agonists for Prostate Cancer
por: Chung, Shiu-Dong, et al.
Publicado: (2014)

Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment
por: Gül, Ülkü, et al.
Publicado: (2016)

Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
por: Mohamad, Nur-Vaizura, et al.
Publicado: (2018)

Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ctvhf1dogctevp9h7fvmgbj9q9